Will developments in allogeneic transplantation influence treatment of adult patients with sickle cell disease?
With improvements in the treatment of children with sickle cell disease (SCD), there has been a significant increase in the number of patients with SCD in adult hematology practice. Quality of life and life expectancy continue to be severely compromised in adult patients; hydroxyurea is the only treatment currently available that could reduce the severity and frequency of painful episodes. Allogeneic stem cell transplantation (SCT) has been offered to children with SCD as a curative option. We discuss the implications of new developments in the field of allogeneic SCT in the treatment of adult SCD patients in light of the experience derived from pediatric transplantation. These developments include innovations in the conditioning regimens, GVHD prophylaxis, and alternative donor SCT and their possible effect on adult SCD patients. Finally, we discuss a nonmyeloablative conditioning protocol for adult SCD patients and the eligibility criteria for adult SCD patients undergoing allogeneic transplantation.
Chakrabarti
Suparno
S
Cancer Research UK Institute for Cancer Studies, University of Birmingham, United Kingdom. suparno@doctors.org.uk
Bareford
David
D
D000328:Adult; D000367:Age Factors; D000755:Anemia, Sickle Cell / Q000628:therapy*; D018380:Hematopoietic Stem Cell Transplantation / Q000379:methods* / Q000639:trends; D006801:Humans; D014019:Tissue Donors; D019172:Transplantation Conditioning / Q000379:methods; D014184:Transplantation, Homologous; D016896:Treatment Outcome